Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
R&D Systems™ Recombinant Human TRAILR1/TNFRSF10A Fc Chimera Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.
Supplier: R&D Systems™ 6949DR100
This item is not returnable.
View return policy
Description
The Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera Protein is derived from CHO. The Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera Protein has been validated for the following applications: Bioactivity.Specifications
Lyophilized from a 0.2μm filtered solution in PBS. | |
40.9 kDa (monomer) | |
100μg | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. | |
APO2, CD261, CD261 antigen, cytotoxic TRAIL receptor, Death receptor 4, DR4, DR4 TRAIL receptor 1, TNF-related apoptosis inducing ligand receptor 1, TNF-related apoptosis-inducing ligand receptor 1, TNFRSF10A, TRAIL R1, TRAIL-R1, TRAILR-1, TRAILR1MGC9365, tumor necrosis factor receptor superfamily member 10A, tumor necrosis factor receptor superfamily, member 10a | |
Unconjugated | |
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
8797 | |
ASP/C3a desArg | |
Chinese Hamster Ovary cell line,CHO-derived human TRAILR1/TNFRSF10A protein, (N-terminus) Human TRAIL R1 (Ala109-Asn239) Accession &Num; AAC51226 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus) | |
Disulfide-linked homodimer | |
ASP/C3a desArg | |
Recombinant |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction